Protocol Ledger

NCT04768075 · Phase III · COMPLETED

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Interventional Phase III clinical trial protocol NCT04768075 sponsored by Guangdong Association of Clinical Trials in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-28 Enrollment: 60 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04768075
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04768075
Protocol FieldVerified Registry Value
NCT IdentifierNCT04768075
Consolidated Lead SponsorGuangdong Association of Clinical Trials
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment60 participants (ACTUAL)
Registered Start Date2021-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI